Table 1.
Baseline characteristics
| Description | Standard care n = 2665 patients |
Ivabradine n = 2648 patients |
||
|---|---|---|---|---|
| Mean/freq | SE/% | Mean/freq | SE/% | |
| Demographics | ||||
| Age (years) | 60.30 | 0.22 | 60.63 | 0.22 |
| BMI (m2/kg) | 28.14 | 28.13 | ||
| Female | 599 | 22.5% | 627 | 23.7% |
| Vital signs | ||||
| Heart rate (bpm) | 79.98 | 0.19 | 79.45 | |
| Systolic blood pressure (mmHg) | 121.78 | 122.25 | ||
| LVEF category | ||||
| <26% | 622 | 23.3% | 633 | 23.9% |
| ≥26%, <30% | 460 | 17.3% | 419 | 15.8% |
| ≥30%, <33% | 742 | 27.8% | 705 | 26.6% |
| ≥33% | 841 | 31.6% | 891 | 33.7% |
| NYHA class | ||||
| II | 1254 | 47.1% | 1264 | 47.7% |
| III | 1361 | 51.1% | 1346 | 50.8% |
| IV | 50 | 1.9% | 38 | 1.4% |
| Medical history | ||||
| HF duration | ||||
| <0.6 years | 628 | 23.6% | 625 | 23.6% |
| ≥0.6, <2 years | 690 | 25.9% | 676 | 25.5% |
| ≥2, <4.8 years | 665 | 25.0% | 696 | 26.3% |
| ≥4.8 years | 682 | 25.6% | 651 | 24.6% |
| Primary cause of heart failure | ||||
| Non-ischemic | 809 | 30.4% | 795 | 30.0% |
| Ischemic | 1856 | 69.6% | 1853 | 70.0% |
| MI | 1564 | 58.7% | 1538 | 58.1% |
| Hypertension | 1791 | 67.2% | 1782 | 67.3% |
| Diabetes | 820 | 30.8% | 781 | 29.5% |
| Prior stroke | 240 | 9.0% | 199 | 7.5% |
| Treatment at randomization | ||||
| Beta-blocker use | ||||
| No beta-blockade | 260 | 9.8% | 260 | 9.8% |
| <half target dose | 1060 | 39.8% | 1062 | 40.1% |
| ≥half target dose, <target dose | 715 | 26.8% | 714 | 27.0% |
| ≥target dose | 630 | 23.6% | 612 | 23.1% |
| ACE inhibitors | 2110 | 79.2% | 2121 | 80.1% |
| ARBs | 355 | 13.3% | 350 | 13.2% |
| Allopurinol | 169 | 6.3% | 162 | 6.1% |
| Loop diuretics | 2096 | 78.7% | 2109 | 79.7% |
SE standard error, BMI body mass index, bpm beats per minute, LVEF left ventricular ejection fraction, HF heart failure, MI myocardial infarction, ARBs angiotensin receptor blockers